SEC Form 4 · accession 0001209191-18-054892
ALBIREO PHARMA, INC. · ALBO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Simon N.R. Harford
Officer — CFO and Treasurer
Period of report
Oct 10, 2018
Accepted (ET)
Oct 12, 2018 · 4:36 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001322505
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Oct 10, 2018 | A | 5,000 | $0.00 | A | 5,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $27.98 | Oct 10, 2018 | A | 37,500 | A | — | Oct 9, 2028 | Common Stock | 37,500 | 37,500 | D |
Explanation of responses
- F1Each restricted stock unit ("RSU") represents the right to receive one share of common stock upon vesting. The RSUs vest as to 25% of the shares on October 10, 2019 with the remainder vesting in equal installments on the last day of 12 consecutive calendar quarters beginning on January 10, 2020 and ending on October 10, 2022.
- F2This option vests as to 25% of the shares on October 10, 2019 with the remainder vesting in equal installments on the last day of 12 consecutive calendar quarters beginning on January 10, 2020 and ending on October 10, 2022.